and medical advisors
Martin J. Madden
Martin J. Madden has a deep and broad background in Medical Device Innovation and New Product Development. During his thirty-year tenure with Johnson & Johnson’s Medical Device organization, Martin was an innovator and research leader for nearly every medical device business including Cardiology, Electrophysiology, Peripheral Vascular Surgery, General and Colorectal Surgery, Aesthetics, Orthopaedics, Sports Medicine, Spine, and Trauma. As an Executive and a Vice-President of Johnson & Johnson, Martin served on the management boards of Johnson & Johnson’s Global Surgery Group, Ethicon, Ethicon Endo-Surgery, DePuy-Synthes, and Cordis, with responsibility for research and development – inclusive of organic and licensed/acquired technology. Martin was also Chairman of J&J’s Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Martin’s leadership experiences spanned internal start-ups, executing turn-around’s, and leading large portfolio and technology intensive research organizations.
In addition to serving on the Board of Mardil Medical, Martin also serves on the Board of Directors of NovoCure, Microbot Medical, and TSO3. Martin has an MBA from Columbia University, an MS in Mechanical Engineering from Carnegie-Mellon University, and a BS in Mechanical Engineering from the University of Dayton.
Aaron has spent over 20 years successfully developing implantable medical devices and delivery systems at SCIMed Lifesystems, Boston Scientific, Urologix, CVRX and Acorn Cardiovascular. One of Aaron’s most notable developments was a novel cardiac implant and minimally invasive delivery procedure which Mardil has acquired the intellectual property for, and will be leveraging in its own innovative minimally invasive product and procedure. Aaron lives in Brooklyn Park, MN with his wife Heather and three children.
Director of Clinical and Regulatory
Sarah Hase joined Mardil Medical in June 2016. She brings 10+ years of experience in the medical device industry, leading successful global clinical research programs from feasibility through post-market phases and exceeding business goals through streamlined processes and high-performance teams. The majority of Sarah’s experience lies in clinical research in the cardiovascular space, including heart failure, valve replacement, peripheral artery disease, and rhythm management, developing research partnerships with physicians and key opinion leaders and working to bring new therapies to market. Sarah holds Bachelor of Science degrees in Biology and Physiology from the University of Minnesota and maintains Certified Clinical Research Associate (CCRA) credentialing through the Association of Clinical Research Professionals (ACRP). Sarah lives in Otsego, Minnesota with her husband Zachary and two daughters.
Mercedes Dullum, MD
Chief Medical Officer
Dr. Dullum is a surgeon with over 30 years of clinical practice as a cardiothoracic surgeon with numerous leadership roles in both hospital settings, private practice and integrated medical practices. She is a leader in her field and a pioneer in minimally invasive cardiac surgery. Dr. Dullum has participated in multiple medical device trials and device innovation particularly in the area of heart failure and minimally invasive surgery. She was one of the original investigators in the Acorn trial. She has multiple publications and has presented her work both Nationally and Internationally. Her expertise also includes clinical outcomes management serving as the Chairman, Performance Improvement Council, Cleveland Clinic Florida and previously as the Medical Director of Clinical Outcomes of Washington Hospital Center. She has also served nationally on the Society of Thoracic Surgeons Quality Assurance and Patient Advocacy Workforce on National Database as an FDA expert panel member and CMS MCAC panel member. She also implemented the Telemedicine program for Cleveland Clinic Florida.
Dr. Dullum received her undergraduate degree from Georgia Institute of Technology and her MD degree from the Medical College of Georgia. She did her residency in General Surgery at the University of Mississippi under Dr. James D Hardy and her cardiothoracic training at George Washington Medical Center.
George Gellert, MD
Chief Imaging Advisor
Medical Dir. Interventional Echocardiography, Banner Univ. Med. Ctr., Phoenix, AZ
Dr. Gellert is a cardiac anesthesiologist with primary interest of 3-Dimensional Interventional Echocardiography. He presently serves as Medical Director of Interventional Echocardiography at Banner University Medical Center Phoenix, Arizona. Dr. Gellert is Board Certified by the American Board of Internal Medicine, the American Board of Echocardiography and the American Board of Anesthesiology.
Dr. Gellert has been in private practice for 24 years with Valley Anesthesiology Consultants in Phoenix, Arizona, and also on faculty at University of Arizona College of Medicine, Creighton University School of Medicine and Mayo Clinic College of Medicine.
Dr. Gellert is a consultant, trainer and proctor for Edwards LifeSciences THV TAVR, Medtronic HVT TAVR Global Field Team, Abbott Structural MITRACLIP, Philips HealthCare US and Siemens Medical US.
Dr. Gellert’s imaging courses and on-site proctoring have provided both surgical and interventional 3D-echocardiography education and hands-on training to hundreds of cardiologists, cardiac anesthesiologists and cardiac sonographers across the United States.
William Cohn, MD
Senior Medical/Surgical Advisor
Director of Minimally Invasive Cardiac Surgery, Texas Heart Institute, Houston, TX
William E. “Billy” Cohn, MD, is a professor of surgery at Baylor College of Medicine and an adjunct professor of bioengineering at both Rice University and the University of Houston. His major research interests include the development of new technology for decreasing the invasiveness of cardiac and vascular surgery. Dr. Cohn has a passion for medical device development and has more than 90 US patents granted or pending, and another 60 international patents for his medical innovations. His numerous awards include an honorary doctorate in science from Oberlin College, the Distinguished Scientist Award, given by the MacDonald Fund, and the Edison Award for excellence in human-centered design and innovation for inventing the SentreHEART® Lariat® Suture Delivery Device.
In 2000, Dr. Cohn was named the distinguished Inventor of the Year by the U.S. Intellectual Property Owners Association and in 2014, he was named Outstanding Inventor of the Year by the Houston IPO. In addition, in 2014 he received an award for the most Innovative Medical Device Startup of the year at the Innovations in Cardiovascular Interventions Conference in Tel Aviv for inventing the TVA Everlinq system for percutaneous creation of AV fistulas and for founding TVA Medical. In 2015, he was awarded a Lifetime Achievement Award for healthcare innovation by the Houston Technology Center. In 2016, he accepted a full time role with Johnson & Johnson to lead the creation of the Center for Device Innovation at Texas Medical Center, a broad, new collaboration between J&J and TMC that aims to accelerate end-to-end development of breakthrough medical devices. Dr. Cohn’s service to Mardil and his vital role in the emergence of the VenTouch® System is one engagement that he has secured to continue forward.
Board of Directors
Andy Betts is a retired audit partner from Ernst & Young where he spent thirty seven years serving publicly and privately held companies in the manufacturing, technology, financial services and insurance industries. Andy has extensive experience in Securities and Exchange Commission reporting and in working with mergers and acquisitions. He served as Director of Audit for the Raleigh office managing staff resources and client assignments for a professional staff of over 100. Andy also worked on a National task force to innovate audit services to clients through technology and other audit tools. He currently serves as a consultant on accounting matters and works part time as an audit director for BDO, USA in Raleigh.
Andy is on the board of Builders Mutual Insurance Company where he serves on the audit and governance committees. He also is on the board of Athene Annuity and Life Assurance Company where he serves on the audit committee. He serves on a number of local community and civic organizations and is currently board chair of StepUp Ministry.
Andy is a graduate of the University of North Carolina at Chapel Hill and the Executive Program of the Kellogg Graduate School at Northwestern University. He is a Certified Public Accountant, a member of the American Institute of CPAs and the NC Association of CPAs, a Fellow of the Life Management Institute and a Chartered Life Underwriter.
Ramesh is a General Partner at Ventureast Fund Advisors India and has been on Mardil’s Board since 2007. He focuses on Life Science, Healthcare, and Clean Environment investments at the firm. He has been with Ventureast for over 15 years, and was part of the APIDC team prior to its partnership with Ventureast where he served as General Partner of APIDC Fund and Biotechnology Venture Fund. He has worked closely with over 50 early to growth-stage companies in pharmaceuticals, specialty chemicals, manufacturing, infrastructure services, healthcare, dairy products, and alternative fuels. He started his career in 1978 as a Chemical Engineer with Bhabha Atomic Research Center. He also worked as Scientific Officer at Reactor Research Center, Kalpakkam and served at Bakelite Hylam. He is a Director for 10 companies, which include portfolio companies as well as a group companies of Ventureast. He holds an M.B.A. in Marketing and Finance from the Indian Institute of Management, Bangalore and B.Tech. degree in Chemical Engineering from REC Warangal.
Hilary has been holding the position as Vice President of Strategic Investment at National Innovation Agency Malaysia (AIM) for over 7 years, focusing on green-field technology investments in Life Sciences, Healthcare, and MedTech. Throughout her career at AIM, her major roles are to orchestrate the whole investment value chain including to lead thorough due diligences of each investment portfolio, implement strategies of technology transfer, deal negotiations, and post-acquisition management. Besides being the secretariat member of the Investment Committee of Public Funds (ICPF) to evaluate all project KPIs and performance management at Research, Development and Commercialization (R, D, C) stages in Malaysia, Hilary is also the active committee member of Horizon Scanning Committee in Ministry of Health to assess and approve all new innovations to be introduced in Malaysia across the entire healthcare related space. Prior to the current attachment with AIM, she has devoted her whole career as the regional heads in business development and clinical affairs in biopharma and nutraceutical MNCs to drive and support global teams in various deal structures, clinical collaborations, market access, pricing and reimbursements. Hilary is a registered pharmacist holding a MSc in Healthcare Industries Management from ESSEC School of Business and BSc in Pharmaceutical Sciences from Ohio State University.
Martin J. Madden
Martin J. Madden has a deep and broad background in Medical Device Innovation and New Product Development. He is a noted innovator, a leader of technology, and a leader of leaders. His passion is to bring exceptional new products and technologies to the market; and to enable engineers, scientists and leaders to thrive and realize their fullest potential.
During his thirty year tenure with Johnson & Johnson’s Medical Device organization, Martin was an innovator and research leader for nearly every medical device business including Cardiology, Electrophysiology, Peripheral Vascular Surgery, General and Colorectal Surgery, Aesthetics, Orthopaedics, Sports Medicine, Spine, and Trauma. During his tenure, thousands of products were launched, scores of leaders developed, and millions upon millions of patients treated. As an Executive and a Vice-President of Johnson & Johnson, Martin served on the management boards of Johnson & Johnson’s Global Surgery Group, Ethicon, Ethicon Endo-Surgery, DePuy-Synthes, and Cordis, with responsibility for research and development – inclusive of organic and licensed/acquired technology. Martin was also Chairman of J&J’s Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Earlier in his career, Martin was a medical device engineer and innovator, and a leader of cross-functional teams charged with incubating, developing, and launching new products.
Martin’s leadership experiences spanned internal start-ups, executing turn-around’s, and leading large portfolio and technology intensive research organizations with annual investments exceeding $1 Billion. Additionally, among the numerous L&A deals and integrations, the most notable have been Biosense, Synthes, Omrix Biopharmaceuticals, and Ultracision.
Martin graduated with honors from Columbia University’s MBA program (#1 in class) and an honors graduate from Carnegie-Mellon University (Master’s degree in Mechanical Engineering), and a Summa cum Laude graduate from the University of Dayton (Bachelor’s degree in Mechanical Engineering). Martin is a past member of the University of Dayton’s School of Engineering Advisory Council.
Martin currently serves on the Board of Directors of NovoCure Limited (NVCR) and Microbot Medical Inc. (MBOT).
James C. Hart, MD, FACC, FACS
Dr. Hart practiced cardiovascular and thoracic surgery for over twenty years in Pennsylvania. He was actively involved in the early development of minimally invasive cardiac surgery and served on the Board of Directors the International Society of Minimally Invasive Cardiac Surgery. He is a Fellow of the American College of Surgeons and the American College of Cardiology.
He left practice in 2003, electing to join Johnson & Johnson to focus on the development of innovative surgical devices and biologics. He served in a number of Medical Affairs and Evidence Based Medicine roles and became Chief Medical Officer and VP Medical Affairs for Johnson & Johnson Global Surgery. He was the recipient of the prestigious Johnson Medal for work on human plasma based biologic products for use in surgery.
After retiring from J&J in 2014, he has remained active and has consulted for a number of broadly based biotech companies. He is on the Board of Directors at VasoPrep Surgical and is Chief Medical Officer at Carmell Therapeutics, focusing on the development of human plasma based products for use in regenerative medicine.
Dr Hart received his undergraduate degree in Chemistry from Carnegie Mellon University and his MD from the Pennsylvania State University. He completed residencies in Surgery and Thoracic Surgery at Penn State, achieving Board certification in each.
Maurice E. Sarano, MD
Director Valvular Heart Disease Clinic at Mayo Clinic, Rochester, MN
William E. Cohn, MD, PhD
Director, Minimally Invasive Surgery, Texas Heart Institute, TX
Robert Schwartz, MD
Minneapolis Heart Institute, MN
Eugene Grossi, MD
New York University, NY